The ADAPT-Sepsis trial aims to determine whether a treatment protocol based on monitoring CRP or PCT safely allows a reduction in duration of antibiotic therapy in adult patients with sepsis and to assess cost effectiveness. The gene discussed is CRP; the disease is Sepsis.